Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDermatologyAetna TBP Dermoscopy Coverage Update | OpenPayer
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentAetnaPolicy 0188

    Total Body Photography, Dermoscopy and Other Selected Noninvasive Dermatologic Tests

    Customize your policy alerts

    Sign up for Aetna Policy 0188 alerts

    Get alerted when Policy 0188 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage and medical necessity criteria for total body photography (TBP) and dermoscopy and lists noninvasive dermatologic tests considered experimental/investigational; applies to members being evaluated for suspicious or high-risk pigmented skin lesions.

    Policy Summary
    PayerAetna
    PolicyTotal Body Photography, Dermoscopy and Other Selected Noninvasive Dermatologic Tests
    Policy CodePolicy 0188
    Change TypeNo material change
    Effective DateDec 1, 1997
    Last ReviewApr 7, 2023
    Next Review DateFeb 8, 2024
    Key ActionDocument PLA results and the subsequent management decision (biopsy or surveillance) when used to justify downstream claims.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    24 monthsTypical repeat interval
    >=1 of 4Covered indications
    multipleInvestigational technologies
    96904Covered CPT
    >99%PLA reported NPV

    Coverage Criteria

    Medical Necessity

    Covered when ANY of the following conditions are present:

    Covered Indications: Total body photography (TBP) and dermoscopy are medically necessary when used for evaluation of members with a history or close family history of any of the following: atypical nevi; dysplastic nevi; melanoma; non-melanoma skin cancers.N/A

    Repeat studies are not typically required more frequently than every 24 months.

    Experimental and Investigational

    The following interventions are considered experimental and investigational because their effectiveness has not been established:

    Experimental/Investigational Interventions: TBP and dermoscopy for indications other than the covered indications; computerized TBP systems (e.g., MelaFind, MoleMapCD, MoleMate); skin-surface mRNA adhesive patch tests (e.g., Mind.Px); hand-held fluorescent molecular imaging (e.g., Orlucent); confocal scanning laser microscopy; DermTech Nevome; electrical impedance devices; high-frequency ultrasonography; multi-photon laser scanning microscopy; multi-spectral image analysis; non-invasive gene expression patch biopsy (e.g., DermTech PLA); optical coherence tomography; reflectance confocal microscopy (RCM); spectroscopy (electrical impedance and optical, e.g., Dermasensor); teledermatology/teledermoscopy; visual image analysis.
    Policy Summary
    PayerAetna
    PolicyTotal Body Photography, Dermoscopy and Other Selected Noninvasive Dermatologic Tests
    Policy CodePolicy 0188
    Change TypeNo material change
    Effective DateDec 1, 1997
    Last ReviewApr 7, 2023
    Next Review DateFeb 8, 2024
    Key ActionDocument PLA results and the subsequent management decision (biopsy or surveillance) when used to justify downstream claims.
    SourceLink
    On This Page
    Coverage CriteriaCodingProvider Actions and Billing GuidanceBackground and RationaleDefinitionsRevision History
    N/A

    List not necessarily all-inclusive.

    Adjunctive/Not routine use

    Guiding statements and specialty guidance relevant to coverage decisions

    Adjunctive use of genomic and molecular tests: Advanced molecular and genomic tests (including adhesive patch mRNA assays and gene expression profiling) should be used as adjuncts to clinical and dermoscopic assessment for lesions clinically or dermoscopically suspicious for melanoma and are not recommended as routine baseline genetic testing outside clinical studies.

    NCCN and specialty guidance emphasize adjunctive use and caution regarding routine baseline genetic testing.

    Coverage considerations and criteria

    Evidence-based considerations and inferred coverage stance from diagnostic accuracy reviews

    Baseline clinical evaluation: Systematic application of best practice (clinical history, naked-eye examination, and 7-point checklist) plus dermoscopy should be performed as the primary evaluation for suspicious pigmented lesions.

    Walter et al (2012) found no benefit of MoleMate over systematic best practice; best practice alone was more accurate than MoleMate.

    Adjunctive testing justified when: Adjunctive noninvasive tests (e.g., CAD systems, RCM, OCT, HFUS) may be considered when lesions remain equivocal after standard clinical and dermoscopic assessment or when test results would be expected to change management (biopsy versus monitoring), recognizing each modality's limitations.

    RCM and OCT may have roles in equivocal lesions or BCC assessment; CAD systems show high sensitivity but variable specificity and limited applicability to community settings.

    Evidence quality requirement: Adoption of advanced diagnostic modalities should account for evidence limitations: many studies are small, at high or unclear risk of bias, conducted in selected populations, and may not reflect real-world performance.

    Multiple systematic reviews called for prospective comparative studies before broad adoption.

    Evidence-based coverage considerations (summary)

    Evidence synthesis and guidance-based stance from the document:

    RCM diagnostic evidence: RCM demonstrates higher sensitivity than dermoscopy for certain equivocal lesions and may reduce unnecessary excisions in some settings, but evidence is of variable quality and insufficient to establish definitive diagnostic use for BCC or cSCC across populations; misclassification risks require further research.

    Cochrane reviews note methodological limitations and applicability concerns.

    Teledermatology diagnostic evidence: Teledermatology/teledermoscopy studies report generally high sensitivity for detecting malignant lesions but variable specificity; most studies were from specialist settings, limiting generalizability to primary/community care.

    Summary sensitivity and specificity estimates vary across reviews.

    Electrical Impedance Spectroscopy (EIS): EIS and related device-based adjuncts have shown promise in pilot and pooled studies for improving biopsy selection metrics, but studies are often small or methodologically limited and additional large real-world trials are needed before routine adoption.

    Evidence includes pilot studies and systematic reviews reporting sensitivity and NNB improvements.

    Emerging molecular/optical tests: Precision transcriptomic tests (e.g., Mind.Px) and fluorescent molecular imaging (e.g., Orlucent) currently lack published clinical outcome or net health benefit data and should be considered investigational pending further evidence.

    No published clinical practice outcome studies available for these technologies.

    Background / Evidence

    Informational/background content; no formal coverage decision language in these sections.

    Evidence summaries: Background statements note that Mind.Px and Orlucent lack published clinical outcome data demonstrating net health benefit; that diagnostic accuracy and reproducibility vary across modalities; and that pathologist interpretation of intermediate lesions shows limited reproducibility and accuracy.

    These are background evidence statements, not coverage criteria.

    The policy lists ICD-10 codes that are applicable when selection criteria for TBP and dermoscopy are met and identifies codes that are not covered for certain adhesive patch gene-expression assays. Specifically, ICD-10 codes for psoriasis (L40.0–L40.9) are listed as not covered when selection criteria relate to gene-expression adhesive patch tests (e.g., DermTech-style PLA/Mind.Px) and similar skin-surface mRNA assays.

    The DermTech Pigmented Lesion Assay (PLA) has a documented technical limitation: it cannot be applied to mucous membranes, the palms of the hands, or the soles of the feet. Providers must avoid using the adhesive patch on these anatomic sites when ordering or performing PLA.

    Gene expression profiling and other molecular prognostic assays for primary cutaneous melanoma remain investigational for routine baseline use. The policy states that routine (baseline) genetic testing of primary cutaneous melanomas (before or following sentinel lymph node biopsy) is not recommended outside of a clinical study, owing to inconsistent gene-signature results and lack of validated prognostic utility.

    Systematic reviews cited in the policy found insufficient evidence to support routine use of high-frequency ultrasonography (HFUS) or optical coherence tomography (OCT) for diagnosis of melanoma or cutaneous squamous cell carcinoma (cSCC). The Cochrane reviews concluded that data are scarce and of limited quality; while preliminary OCT data suggest a potential role for OCT in diagnosing basal cell carcinoma (BCC), the evidence is inadequate to recommend routine clinical use of HFUS or OCT for melanoma or cSCC.

    Emerging precision medicine and imaging technologies discussed in the policy currently lack published clinical outcome evidence demonstrating net health benefit. The policy identifies Mind.Px (a dermal biomarker patch with NGS transcriptomic analysis) and Orlucent (hand-held fluorescent molecular imaging) as technologies with no available published clinical outcome studies to support effectiveness in routine care.

    The policy presents Mind.Px and the Orlucent fluorescent molecular imaging system as having insufficient evidence of effectiveness. Both are described as investigational in the absence of published clinical outcome data, and the document treats them as technologies not supported for routine clinical decision-making.

    This Clinical Policy Bulletin is provided as a summary description of plan benefits and clinical evidence and does not constitute a contract or guarantee of coverage. Aetna states that the bulletin contains only a partial, general description of plan or program benefits and is subject to updates and change.

    The policy classifies a range of computerized TBP systems and multiple advanced imaging or diagnostic technologies as experimental/investigational for evaluation of dysplastic and atypical nevi. Examples listed include computerized TBP systems (e.g., MelaFind, MoleMapCD, MoleMate), non-invasive gene-expression patch assays (e.g., DermTech PLA, Mind.Px), reflectance confocal microscopy, optical coherence tomography, electrical impedance devices, high-frequency ultrasonography, multi-photon microscopy, multi-spectral image analysis, spectroscopy, and teledermatology; these modalities are considered investigational because their effectiveness for early detection in this indication has not been established.

    The policy cautions against adoption of these advanced diagnostic tools in primary care settings without evidence that their accuracy matches dermatology-clinic validation studies. Review authors and technology assessments noted that many accuracy studies were performed in specialist dermatology clinics, raising concerns about applicability when used outside those settings and the risk of inappropriate overuse for patient reassurance rather than clinically indicated assessment.

    Current evidence does not support routine use of computerized CAD systems, HFUS, OCT, or RCM as standalone replacements for standard clinical assessment and dermoscopy. Systematic reviews cited methodological limitations, small or selected study populations, and variable test performance, and therefore recommend these modalities be considered adjuncts rather than primary diagnostic replacements.

    Reflectance confocal microscopy (RCM) and other emerging imaging modalities have limited and heterogeneous evidence; the policy states that substituting RCM or similar methods for standard clinical examination and dermoscopy is not supported by sufficient evidence. RCM may have an adjunctive role in selected equivocal cases, but it is not endorsed as a replacement for clinical/dermoscopic evaluation.

    The policy explicitly states that investigational tests such as Mind.Px and Orlucent are not supported for routine clinical decision-making due to lack of published clinical outcome data and established clinical utility. These technologies are categorized as investigational/experimental in this clinical context.

    Coding

    Covered CPT CodesCPTCovered
    96904Whole body integumentary photography, for monitoring of high-risk patients with dysplastic nevus syndrome or a history of dysplastic nevi, or patients with a personal or family history of melanoma.
    Codes associated with investigational/non-covered technologiesmixedNot Covered
    0089UOncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es).
    0258UAutoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics.
    0470TOptical coherence tomography (OCT) for microstructural and morphological imaging of skin, image acquisition, interpretation, and report; first lesion.
    0471TEach additional lesion (OCT).
    0658TElectrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score.
    0659T(Code text in document truncated/not relevant to dermatology).
    0700TMolecular fluorescent imaging of suspicious nevus; first lesion.
    0701TEach additional lesion (molecular fluorescent imaging).
    96931Reflectance confocal microscopy (RCM) for cellular and sub-cellular imaging of skin (group includes 96931-96936).
    ICD-10 Codes (covered and not covered)ICD-10
    C43.0-C43.9Malignant melanoma of the skin
    D22.0-D23.9Melanocytic nevi and other benign neoplasms of the skin
    Z80.8Family history of malignant neoplasm of other organs or systems
    Z85.820Personal history of malignant melanoma of skin
    Z85.828Personal history of other malignant neoplasm of skin
    Z86.018Personal history of other benign neoplasm (dysplastic nevus)
    Z87.2Personal history of diseases of the skin and subcutaneous tissue (atypical and dysplastic nevus)
    L40.0-L40.9Psoriasis

    Provider Actions and Billing Guidance

    Prior Authorization

    Prior Authorization Recommended for Emerging/Precision Tests

    Prior authorization consideration — Some advanced or emerging tests may require prior authorization. When using precision or investigational modalities (e.g., Mind.Px, Orlucent, novel genomic assays), confirm benefit coverage and obtain authorization if plan rules or local medical management require it before testing.

    • When CPT 96904 (whole body integumentary photography) is used, ensure selection criteria and diagnosis codes align with policy.
    • Emerging/precision tests without established clinical outcome data (Mind.Px, Orlucent) should trigger discussion with the plan for prior authorization due to uncertain utility.
    Denial Risk

    Denial Risk for Investigational Technologies

    Denial risk for investigational technologies — Tests and services described in the policy as experimental, investigational, or lacking evidence may be denied if submitted for coverage. Document medical necessity thoroughly when requesting coverage for less-established technologies.

    • Services billed using codes for computerized TBP systems or listed experimental technologies (e.g., MelaFind, MoleMapCD, MoleMate, Orlucent, Mind.Px) may be denied.
    • If submitting requests for investigational tests, include supportive evidence, rationale for clinical use, and prior authorization outcomes where applicable.
    Documentation Required

    Document PLA Result and Follow-up Plan

    Document PLA results and management plan — For DermTech PLA (pigmented lesion assay), document the test result (positive/negative and gene findings) and the subsequent management decision (biopsy type or surveillance interval).

    • Record whether PLA detected LINC00518, PRAME, or both and the corresponding clinical interpretation.
    • If PLA(−), document the planned surveillance strategy (interval, modality — e.g., dermoscopy/TBP) and follow-up duration; if PLA(+), document biopsy approach and pathology follow-up.
    Documentation Required

    Follow-up Documentation for PLA(−) Results

    Follow-up documentation for PLA(−) results — Studies routinely managed PLA(−) lesions with clinical surveillance rather than biopsy. When choosing surveillance, clearly document rationale, follow-up intervals (eg, 3–12 months), and criteria that would prompt biopsy.

    • Describe surveillance method (dermoscopy, TBP, teledermatology) and expected reassessment timeframe (e.g., 3–6 months; note some lesions may require longer follow-up up to 12 months).
    • If additional risk factors, persistent clinical suspicion, or patient concern exist, document reasons for opting for biopsy despite PLA(−).
    Documentation Required

    Document Clinical Decision-Making and Role of Adjunctive Tests

    Clinical decision-making documentation — Noninvasive tests are adjuncts to, not replacements for, clinical evaluation and dermoscopy. Document that test selection was based on clinical history, naked-eye exam, and dermoscopic findings, and how adjunctive test results informed the management plan.

    • State that dermoscopic evaluation was performed and summarize key findings (7-point checklist or equivalent).
    • Document that adjunctive tests (PLA, RCM, HFUS, CAD systems) were used to supplement, not substitute, the clinical/dermoscopic assessment and how results changed management.
    Documentation Required

    MoleSafe / TBP Documentation Elements

    MoleSafe and TBP documentation elements — When using comprehensive imaging systems (e.g., MoleSafe, TBP), include description of the imaging series and dermoscopy elements in the record to support medical necessity for monitoring high-risk patients.

    • Document that total body photography captured the expected series (eg, ~25 images covering ~96% of body surface for MoleSafe) and whether total body dermoscopy was performed.
    • When billing CPT 96904, include indication (history of atypical/dysplastic nevi, personal/family history of melanoma) and frequency justification (usually not more frequent than every 24 months).
    Documentation Required

    Reference-Standard and Pathology Documentation

    Reference-standard and pathology documentation — For validation or diagnostic confirmation, document the reference standard used (histologic confirmation or clinical follow-up) and include biopsy pathology reports and any second opinions when pathology is ambiguous.

    • If a lesion is biopsied, include histopathology results and note concordance with noninvasive test findings.
    • For intermediate or discordant pathology (eg, moderately dysplastic to early invasive melanoma), document any additional pathology review or expert consultation.
    Note

    Dermoscopy as First-line and Adjunctive Test Use / Best Practice

    Adjunctive test use and best practice — Dermoscopy remains the recommended first-line noninvasive evaluation. Adjunctive modalities (gene expression assays, RCM, HFUS, CAD systems) may be used selectively as supplements to systematic clinical assessment (history, naked-eye exam, 7-point checklist, dermoscopy).

    • Document that standard diagnostic steps (history, naked-eye exam, 7-point checklist, dermoscopy) were completed prior to adjunctive testing.
    • Use adjunctive tests for specific clinical questions (eg, avoid unnecessary biopsy, margin assessment) and document why the adjunctive test was chosen.
    Note

    Investigational / Insufficient Evidence — Coverage Considerations

    Investigational / insufficient evidence — Novel tests without robust, generalizable outcome data (e.g., Mind.Px, Orlucent, some RCM uses, electrical impedance devices) are considered investigational or have insufficient evidence for routine coverage. Use within research or with prior authorization and strong documentation of rationale if considered clinically necessary.

    • Mind.Px and Orlucent currently lack published clinical outcome data demonstrating net health benefit.
    • Reflectance confocal microscopy (RCM) and other emerging modalities have variable evidence quality; document applicability and limitations if used in practice.
    Note

    No Specific Authorization/Denial Trigger Specified

    No specific authorization/denial trigger specified in this section — The policy lists experimental/investigational technologies and covered CPTs (eg, 96904) but does not define explicit automatic authorization or denial triggers; providers should follow standard prior authorization processes and submit clinical documentation when requesting coverage for nonstandard tests.

    • When in doubt, obtain prior authorization and include clinical history, dermoscopic findings, prior management steps, and rationale for the requested test.
    • Absent explicit PA rules here, local plan requirements and medical management teams determine authorization; maintain complete documentation to expedite review.

    Background and Rationale

    Total body photography (TBP) and dermoscopy are established, evidence-supported techniques for detecting and monitoring dysplastic and atypical nevi to facilitate early detection of malignant cutaneous lesions. The policy notes that dermoscopy improves diagnostic accuracy compared with unaided inspection and that TBP is useful for monitoring patients with numerous nevi or high melanoma risk; biopsy and histopathology remain the diagnostic gold standard.

    Definitions

    Dermoscopy (dermatoscopy, epiluminescence microscopy)
    DefinitionDermoscopy (dermatoscopy, epiluminescence microscopy) uses a handheld magnification tool (dermoscope) with high-intensity light (often oil immersion or polarized lenses) to visualize subsurface patterns and structures of pigmented skin lesions to improve discrimination of benign from malignant lesions.
    Typical magnificationApproximately 10x or higher magnification using a dermoscope.
    Clinical roleImproves diagnostic accuracy vs unaided inspection by ~20–30% and is the standard first-line noninvasive diagnostic approach for suspicious pigmented lesions.
    Imaging vs storageDermoscopy can be combined with cameras and software to capture and archive images for comparison over time (digital dermoscopy/video-dermoscopy).
    Total body photography (TBP / mole mapping)
    DefinitionTotal body photography (TBP / mole mapping) is digital whole-body imaging using standardized photography to record and archive skin lesions for comparison over time to detect new or changing nevi.
    Use caseUseful for patients with numerous nevi or those at high risk of melanoma to monitor lesion change during regular examinations.
    FormatsMay include series of standardized photos or video-dermoscopy; images can be linked with dermoscopic images and stored for longitudinal comparison.
    SIAscopy / SIAscope
    DefinitionSIAscopy / SIAscope is a spectrophotometric intracutaneous analysis method that noninvasively analyzes dermal pigment, vascularity, and collagen integrity to characterize pigmented skin lesions and produces dermoscopic-style images for training and archiving.
    Diagnostic performanceIn small prospective studies SIAscopy showed high sensitivity (e.g., 100% in one study) but lower specificity than dermoscopy in some cohorts.
    Clinical roleHolds potential advantages for image archiving and training but dermoscopy remains the best pre-operative diagnostic tool in reported studies.
    MelaFind
    DefinitionMelaFind is a noninvasive computer-vision system designed to aid detection of early pigmented cutaneous melanoma by analyzing lesion images with automated algorithms.
    Validation evidenceA large prospective multicenter study evaluated 1,632 lesions (127 melanomas) and reported measured sensitivity of 98.4% but very low specificity (~9.9% in one analysis).
    Clinical considerationHigh sensitivity but low specificity raises questions about clinical usefulness due to many false positives despite safety in detecting melanoma.
    Pigmented Lesion Assay (PLA)
    DefinitionPigmented Lesion Assay (PLA) is an adhesive patch-based, noninvasive gene-expression test (DermTech) that collects epidermal material via an adhesive patch to measure gene expression associated with melanoma (e.g., CMIP, LINC00518 and in some validations PRAME).
    Intended useUsed to help rule out melanoma and potentially reduce unnecessary surgical biopsies of clinically atypical pigmented lesions; may aid decisions between biopsy and surveillance.
    LimitationsPatch biopsy cannot be used on mucous membranes, palms, and soles; performance in studies varied with validation cohorts reporting ~91% sensitivity and ~69% specificity (Gerami 2017).
    Electrical Impedance Spectroscopy (EIS)
    DefinitionElectrical Impedance Spectroscopy (EIS) is a noninvasive technique that measures electrical impedance differences between skin tissues and uses classification algorithms to help distinguish malignant from benign lesions.
    Performance characteristicsClinical trials reported very high sensitivity (~98%) with low specificity (~23–25%) for some algorithms; integration with clinician assessment has been associated with improved biopsy selection metrics (reduced NNB).
    Clinical roleMay be used as an adjunct to visual inspection/dermoscopy to improve biopsy selection, particularly for clinically challenging lesions, but limitations in specificity warrant cautious use.
    Pigmented Lesion Assay (PLA) — commercial test (LINC00518, PRAME)
    DefinitionPigmented Lesion Assay (PLA) commercial implementation measures expression of LINC00518 and PRAME (2-gene or 2-GEP) from adhesive patch-collected RNA to help rule out melanoma and guide biopsy decisions.
    Validation evidenceGerami et al (2017) validation of LINC00518 and PRAME reported ~91% sensitivity and ~69% specificity in 398 validation samples; real-world registries reported high NPV (>99%) but lower PPV (e.g., ~18.7% among biopsied 2-GEP–positive lesions).
    Operational notesPLA-positive lesions in real-world cohorts were biopsied at high rates (~97.5%), while PLA-negative lesions were often clinically monitored rather than biopsied; documentation of follow-up/management is important for utilization review.
    DermTech Nevome
    DefinitionDermTech Nevome is a noninvasive adhesive-patch DNA mutation analysis test that evaluates hotspot mutations (BRAF, NRAS, and TERT promoter) from patch-collected material to identify lesions at higher risk for melanoma.
    Intended useDesigned to be used in conjunction with PLA (ordered when PLA is positive) to provide additional mutation-based risk information for pigmented lesions clinically suspicious for melanoma.
    Evidence statusCurrently limited published clinical evidence regarding clinical value; DermTech states Nevome can be ordered when PLA is positive but independent effectiveness data are lacking.
    Computerized Total Body Photography / MoleMate
    DefinitionComputerized Total Body Photography and systems such as MoleMate are imaging platforms combining whole-body photography with computer-assisted analysis to support objective lesion assessment and referrals.
    Clinical trial findingsRandomized trial of the MoleMate system in primary care showed no improvement in appropriateness of referral vs best-practice assessment; best-practice plus dermoscopy outperformed MoleMate in referral accuracy.
    Clinical implicationComputerized TBP systems may aid documentation and patient education, but standardized best-practice clinical assessment remains the primary evaluation method before adjunctive system use.
    CAD (Computer-assisted diagnosis)
    DefinitionComputer-assisted diagnosis (CAD) systems are automated or semi-automated image-analysis platforms (e.g., Derm-CAD, Spectro-CAD, multi-spectral imaging) that apply algorithms to lesion images to assist diagnosis of pigmented lesions.
    Performance summarySystematic reviews found CAD systems often have high pooled sensitivity for melanoma detection (e.g., Derm-CAD pooled sensitivity ~90.1%) but variable and sometimes low specificity across technologies and studies.
    Evidence considerationsStudies vary widely in hardware, software, training methods, and populations; many studies have high/unclear bias and limited applicability to general practice, so CAD should be considered adjunctive.
    High-frequency ultrasonography (HFUS)
    DefinitionHigh-frequency ultrasonography (HFUS) refers to ultrasound imaging at frequencies ≥20 MHz used to assess lesion morphology and depth in pigmented and nonpigmented skin lesions.
    Evidence statusCochrane review identified few and low-quality studies with heterogeneous methods; data insufficient for meta-analysis and routine diagnostic accuracy for melanoma or cSCC is not established.
    Clinical rolePreliminary studies suggest potential to assess lesion depth and morphology but limitations in visualization and variable sensitivity/specificity restrict routine use as a replacement for standard evaluation.
    Optical coherence tomography (OCT)
    DefinitionOptical coherence tomography (OCT) is a noninvasive imaging technique providing in vivo cross-sectional images of skin microstructure to aid evaluation of skin lesions.
    Evidence summaryPooled data from limited studies suggest OCT combined with visual inspection and dermoscopy may have high sensitivity for BCC (e.g., ~95% sensitivity) but data are insufficient for melanoma or cSCC detection.
    Clinical implicationOCT may have a potential role in diagnosing clinically challenging BCCs, but small study numbers and variable quality limit definitive practice recommendations.
    Reflectance confocal microscopy (RCM)
    DefinitionReflectance confocal microscopy (RCM) is a high-resolution, in vivo imaging modality that provides cellular-level images approximating histologic resolution to evaluate equivocal skin lesions.
    Diagnostic performanceCochrane reviews and meta-analyses found RCM more sensitive than dermoscopy in many settings (e.g., Pellacani RCM score ≥3 sensitivity ~92%) and with higher specificity in equivocal lesions, but studies had variable quality and applicability concerns.
    Clinical roleRCM may be considered as an adjunct to dermoscopy for equivocal lesions to reduce unnecessary excisions, but insufficient evidence exists to support routine replacement of standard clinical examination.
    Reflectance Confocal Microscopy (RCM) — evidence notes re: BCC and cSCC
    Additional notesRCM evidence for BCC and cSCC is heterogeneous: meta-analyses show higher sensitivity for BCC in equivocal lesions but wide CIs and risk of misclassification (up to ~15% of false positives were melanomas mistaken for BCC); insufficient evidence supports routine diagnostic substitution.
    Clinical cautionPotential role to avoid diagnostic biopsies in lesions with high clinical suspicion of BCC exists, but misclassification risk (including missing melanoma) necessitates further research and careful use.
    Evidence qualityMany RCM studies had high/unclear risk of bias and applicability concerns (selective recruitment, unclear blinding, remote interpretation), limiting generalizability.
    Teledermatology / Teledermoscopy
    DefinitionTeledermatology / Teledermoscopy is the remote evaluation of lesion photographic and/or dermoscopic images transmitted via telecommunications for diagnosis or triage compared with face-to-face specialist diagnosis or histology.
    Diagnostic performanceSystematic review data show generally high sensitivity (e.g., summary sensitivity ~95%) and variable specificity (~84% overall in some analyses) for identifying malignant lesions from images, but study heterogeneity and specialist-image acquisition limit generalizability.
    ApplicabilityMany studies recruited from specialist settings with images acquired by dermatologists or specialist units rather than primary care, which may reduce applicability in community telemedicine settings.
    Electrical Impedance Spectroscopy (EIS) — device-based test
    DefinitionElectrical Impedance Spectroscopy (EIS) devices are noninvasive tools that measure electrical impedance differences between healthy and malignant skin tissues and produce automated scores to assist biopsy decision-making.
    Observed effectsStudies indicate integration of EIS with clinician assessment can improve number-needed-to-biopsy (NNB), increase sensitivity and improve biopsy selection, particularly for clinically challenging lesions.
    LimitationsReported algorithms show low specificity in some trials; study designs, image-only decision contexts, and metric variability (NNB) limit direct translation to routine practice without further validation.
    Mind.Px (Mindera Health)
    DefinitionMind.Px (Mindera Health) is an FDA-registered precision medicine test using a minimally invasive dermal biomarker patch to extract epidermal/dermal mRNA, followed by next-generation sequencing (NGS) of >7,000 biomarkers and machine-learning–derived reports to inform potential biologic treatment response predictions.
    Intended applicationPresented as a predictive/transcriptomic panel to help guide biologic therapy selection in psoriasis rather than as a primary melanoma diagnostic tool.
    Evidence statusNo published clinical practice outcome data or net health benefit studies are currently available; considered investigational for clinical decision-making pending further evidence.
    Orlucent system
    DefinitionThe Orlucent system is a hand-held fluorescent molecular imaging device that applies a topical fluorescent biotag to detect biomarkers of early tissue changes as a mole transitions from benign toward atypia.
    Development statusOrlucent is conducting clinical trials to identify transition thresholds and to document clinical impact; currently there is insufficient evidence of effectiveness for routine clinical use.
    Clinical roleIntended as an in-office point-of-care tool to provide biologic information about mole transformation, but clinical utility and outcome data are not established.
    Noninvasive dermatologic imaging/tests
    DefinitionNoninvasive dermatologic imaging/tests is a collective term for modalities including dermoscopy/epiluminescence microscopy, total body photography, reflectance confocal microscopy, high-frequency ultrasound, optical coherence tomography, electrical impedance spectroscopy, molecular patch tests, computerized CAD systems, multispectral imaging, and fluorescent molecular imaging.
    PurposeThese modalities are intended to improve detection, characterization, monitoring, and biopsy-selection decisions for pigmented and nonpigmented skin lesions as adjuncts to clinical assessment.
    Evidence stanceMany technologies have variable diagnostic accuracy and limited real-world outcome data; several (e.g., Mind.Px, Orlucent, DermTech Nevome, RCM and OCT for some indications) are considered investigational or adjunctive pending stronger evidence.

    Revision History

    2023-04-07policy_reviewLatest

    Policy was last reviewed on 04/07/2023 as shown in the policy history.

    1997-12-01policy_effective

    Policy effective date recorded as 12/01/1997.

    2024-02-08next_scheduled_review

    Next scheduled policy review listed as 02/08/2024.